Inclusion Criteria:

- Acute lymphoblastic leukemia of the mature B-cell type (L3-ALL)

- High-grade non-Hodgkin's lymphoma of the following subtypes (WHO classification)

- Burkitt's lymphoma (including atypical Burkitt's lymphoma)

- Precursor B-lymphoblastic lymphoma

- Anaplastic large-cell lymphoma (Ki1+, B-, T- oder Null-cell-type)

- Mediastinal large B-cell-lymphoma (subtype of diffuse large B-cell lymphoma)

- Age = 18 years

- Patient's Informed Consent

Exclusion Criteria:

- Serious complications caused by leukemia/ lymphoma or by a second illness: e.g.

- Severe, unmanageable complications such as sepsis, pneumonia with oxygen
deficiency,

- Shock, hemorrhage at the time of diagnosis

- Renal insufficiency from leukemia/lymphoma-unrelated causes

- Severe cardiac or hepatic insufficiency

- Severe obstructive or restrictive lung disease that would compromise patient's
treatment with intensified chemotherapy

- HIV infection

- Secondary lymphoma following prior chemotherapy/ radiotherapy or an active
second malignancy

- Known severe allergy to foreign proteins

- Cytostatic pretreatment for B-ALL/lymphoma (exceptions: short-term administration of
steroids = 7 days, single administration of vincristine or cyclophosphamide, one
cycle of CHOP, a single administration in an emergency of other cytostatic agents)
for another malignant disease within the last 5 years

- Pregnancy/ nursing period

- Severe psychiatric illness or other circumstances giving ground to the assumption
that a patient cannot give his consent to therapy or act co-operatively

- Absence of patient's informed consent

- Participation in another clinical study that would possibly interfere with study
therapy